Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Accumulated Expenses (2016 - 2021)

Historic Accumulated Expenses for Sunshine Biopharma (SBFM) over the last 8 years, with Q4 2021 value amounting to $48287.0.

  • Sunshine Biopharma's Accumulated Expenses rose 9854.85% to $48287.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $48287.0, marking a year-over-year increase of 9854.85%. This contributed to the annual value of $48287.0 for FY2021, which is 9854.85% up from last year.
  • Sunshine Biopharma's Accumulated Expenses amounted to $48287.0 in Q4 2021, which was up 9854.85% from $84945.0 recorded in Q3 2021.
  • In the past 5 years, Sunshine Biopharma's Accumulated Expenses ranged from a high of $84945.0 in Q3 2021 and a low of $1171.0 during Q1 2017
  • Over the past 5 years, Sunshine Biopharma's median Accumulated Expenses value was $29140.0 (recorded in 2018), while the average stood at $30247.8.
  • As far as peak fluctuations go, Sunshine Biopharma's Accumulated Expenses tumbled by 6711.35% in 2017, and later soared by 53323.5% in 2018.
  • Over the past 5 years, Sunshine Biopharma's Accumulated Expenses (Quarter) stood at $9215.0 in 2017, then rose by 0.82% to $9291.0 in 2018, then skyrocketed by 126.85% to $21077.0 in 2019, then increased by 15.39% to $24320.0 in 2020, then soared by 98.55% to $48287.0 in 2021.
  • Its Accumulated Expenses was $48287.0 in Q4 2021, compared to $84945.0 in Q3 2021 and $58712.0 in Q2 2021.